Atyr PHARMA INC (NASDAQ:ATYR) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 467.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,532 shares of the company's stock after purchasing an additional 147,092 shares during the period. JPMorgan Chase & Co. owned approximately 0.21% of Atyr PHARMA worth $646,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Atyr PHARMA in the fourth quarter valued at $144,000. American Century Companies Inc. bought a new stake in Atyr PHARMA during the fourth quarter worth approximately $319,000. Victory Capital Management Inc. purchased a new position in shares of Atyr PHARMA in the 4th quarter worth approximately $37,000. Raymond James Financial Inc. bought a new position in shares of Atyr PHARMA during the 4th quarter valued at approximately $39,000. Finally, D.A. Davidson & CO. purchased a new stake in Atyr PHARMA during the 4th quarter valued at $141,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Leerink Partners began coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Friday, March 14th. Cantor Fitzgerald started coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an "overweight" rating on the stock. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $18.60.

Atyr PHARMA Stock Down 3.5 %

Shares of ATYR stock traded down $0.13 during mid-day trading on Monday, hitting $3.48. 189,278 shares of the stock traded hands, compared to its average volume of 902,144. The stock's fifty day moving average is $3.29 and its two-hundred day moving average is $3.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The stock has a market cap of $308.79 million, a P/E ratio of -3.69 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. Equities analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.